Bird's eye view of Lotte Biologics plants in Songdo, Incheon, South Korea (Courtesy of Lotte) South Korea’s retail-to-chemical conglomerate Lotte Group will restructure its bio business to focus on the profit-making medicine bio development manufacturing organization (CDMO) business.Sourc
Celltrion founder and Chairman Seo Jung-jin South Korea’s largest biosimilar maker Celltrion Inc. said on Friday that it has scrapped a plan to merge with Celltrion Pharm Inc., an R&D and local distribution affiliate, in the face of opposition from minority shareholders.They argued th
Celltrion booth at the BIO International Convention 2024 in San Diego, June 2024 (Courtesy of Yonhap) Celltrion Inc., South Korea’s biosimilar giant, will proceed with phase 3 trials for global blockbuster drug Keytruda’s copycat CT-P51, a treatment for non-small cell lung cancer, a
South Korean biosimilar maker Celltrion Inc. said on Monday that its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), has joined the insurance-covered drug lists by three major US Prescription Benefit Managers (PBMs) after its US launch in March.The three PBM
A bird's-eye view of Celltrion's Songdo campus in Incheon, South Korea South Korea’s largest biosimilar maker Celltrion Inc. said on Tuesday that its third plant in Sondgo, west of Seoul, is undergoing process valuation testing, or the final stage of inspection, before starting commercial
SK Pharmteco's headquarters in Sacramento, California SK Inc., the holding and investment company of SK Group, South Korea’s second-largest conglomerate, is negotiating to sell a major asset of its contract drug-making unit SK Pharmteco Co. in the US to Novo Nordisk A/S, a Danish multinat
Celltrion Group founder and Chairman Seo Jung-jin (on left) visiting the Celltrion booth at DDW 2024 WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after a well-known pharmaceutical company in
Celltrion headquarters in Incheon, South Korea South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US market. The drug is a subcutaneous injection of Celltrion’s infliximab Remsima, a treatment for
Celltrion Group founder and Chairman Seo Jung-jin (left) speaks at J.P. Morgan Healthcare Conference (Courtesy of Celltrion) South Korean biosimilar giant Celltrion Group is planning to debut on the Nasdaq market by early 2025, founder and Chairman Seo Jung-jin said at the J.P. Morgan Healthcar
Seo Jung-jin (second from right), founder and chairman of Celltrion, speaks at the J.P.Morgan Health Care Conference on Jan. 10 (Courtesy of Celltrion) Celltrion Inc., South Korea's leading biosimilar maker, on Wednesday expressed its ambition to join the global top 10 biotech and pharmaceutica
GC Cell President and CEO James Park (Courtesy of GC Cell) GC Cell Corp., an affiliate of South Korea’s major pharmaceutical company GC Biopharma Corp., is targeting the cell therapy contract development and manufacturing organization (CDMO) business for global bio-industry leadershop whi
Bird's eye view of Lotte Biologics plants in Songdo, Incheon, South Korea (Courtesy of Lotte) South Korea’s Lotte Biologics Co. is set to start building its first local facility for drug manufacturing next year, aiming for 400,000 liters of global production capacity annually by 2034. The
Samsung Biologics headquarters in Incheon, South Korea (Courtesy of Samsung Biologics) Samsung Biologics Co. is slated to inject 2 trillion won ($1.5 billion) to build its fifth plant in South Korea. It will be a fast follow-up investment as the construction of its fourth plant, the world's lar
Medipost headquarters building Medipost Co, a South Korean biotechnology company, is expanding its cell and gene therapy contract development and manufacturing organization (CDMO) business by building 10 clean rooms and production facilities in the country.The company said on Monday the size of
Medipost headquarters building Medipost Co., a South Korean biotechnology company, has acquired a 39.6% stake in OmniaBio Inc., a Canada-based cell and gene therapy contract development and manufacturing organization (CDMO) firm, for 29.5 billion won, or C$30 million.The stake purchase is aimed
Samsung Group de facto leader Jay Y. Lee points to a diorama of Samsung Biologics' newly built fourth CDMO factory in Songdo, Incheon, on Oct. 11, 2022 (Courtesy of Samsung) South Korea’s Samsung Biologics Co.’s new biopharmaceuticals plant launched operations on Tuesday, a move exp
Aerial view of Discovery Labs, which houses The Center for Breakthrough Medicines (CBM) SK Inc., the holding company of SK Group, announced Sunday that it invested $350 million into Pennsylvania-based Center for Breakthrough Medicines (CBM.)With the latest investment, SK became the second-large
CHA Biotech CEO Oh Sang-hoon explains the production of cell therapies at the company’s research center in South Korea. CHA Biotech, South Korea’s stem cell therapeutics developer, is set to expand its biomaterials contract development and manufacturing organization (CDMO) business.